ClinicalTrials.gg
TerminatedNCT05006573MAHALEUpdated Jul 20, 2025Results posted

Efficacy and Safety of Benralizumab in Patients With Non-cystic Fibrosis Bronchiectasis

A Phase 3 interventional study of Benralizumab and Placebo to Benralizumab in Non-cystic Fibrosis Bronchiectasis, sponsored by AstraZeneca. Terminated at 48 sites in 16 countries. Open to participants aged 18 Years to 130 Years. Per ClinicalTrials.gov, last updated 2025-07-20.

Sponsored by AstraZeneca · Phase 3, Interventional, and Treatment

Why this study was terminated
Due to the decision to stop recruitment early, enrolment into the MAHALE trial was terminated in August 2022; 139 patients were screened and 100 randomised to IP.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
100
Allocation
Randomized
Ages
18 Years to 130 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 65 studies in Bronchiectasis with a site in United States — 21 open to participants now, 23 under way, 2 of them phase 3. Bronchiectasis · United States.

Enrollment
23rd of 52
100 · median 78
Started
2021
with 2 others
Phase 3
14 of 65
2 open now
Registered
39th of 65
by date
Lead sponsor
2 of 65
AstraZeneca

Among the 65 studies in Bronchiectasis with a site in United States, this one is the 23rd largest by enrollment of the 52 interventional ones that give a count, is one of 3 that started in 2021, is one of 14 in phase 3, and was the 39th registered.

Bronchiectasis

404 studies on the registry are indexed under Bronchiectasis; 125 are open to participants now.

Browse Bronchiectasis studies →

Open to participants now

21 of the 65 studies in Bronchiectasis with a site in United States are open now. Recruiting first, the newest first:

16 more — sign in →

All 21 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 93 Bronchiectasis studies recruiting now, 50 (54%) set no upper age limit and 13 (14%) stop at 75 or younger; 12 take children under 18; 26 take healthy volunteers.

This study: 18 Years to 130 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 65 studies in Bronchiectasis with a site in United States, or all of them as a file.
02

Study summary

This is a multicentre, randomised, double-blind, parallel-group, placebo-controlled, phase III study originally designed to test the hypothesis that benralizumab will reduce exacerbation rates compared with placebo on top of standard-of-care therapy in adult patients with non-cystic fibrosis bronchiectasis with eosinophilic inflammation (NCFB+EI).

All patients who complete the double-blind treatment period (28 to 52 weeks depending on the timing of patient randomization and when the revised CSP version 3.0 becomes effective) on investigational product (IP) may be eligible to continue into an open-label extension (OLE) period during which all patients will receive benralizumab.

The revised OLE period is intended to allow patients approximately 32 weeks of treatment with open label benralizumab (24 weeks followed by a FU visit 8 weeks after the last dose of IP for a total of approximately 32 weeks).

03

Conditions studied

  • Non-cystic Fibrosis Bronchiectasis

Browse trials for

Keywords

  • Benralizumab
  • Non-cystic Fibrosis Bronchiectasis
  • Eosinophlic Inflammation
04

Who can participate

Ages eligible
18 Years to 130 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female, at least 18 years of age inclusive at the time of signing the ICF
  • Must have NCFB diagnosed by a physician and confirmed by CT (measured at screening; if a new CT is not possible, a CT performed within 12 months of the screening visit is acceptable).
  • Documented history of 2 or more bronchiectasis exacerbations within a year of the screening visit.
  • If receiving prophylactic systemic or inhaled antibiotics to prevent bronchiectasis exacerbations, the dose/regimen must be stable for at least 3 months prior to the screening visit and remain stable throughout the DB period of the study. If prophylactic macrolides have been recently discontinued, patients must have been off treatment for at least 3 months prior to randomisation. In all other cases of prophylactic antibiotic use, ≥ 4 weeks wash out period should be in place after the last dose of antibiotic and prior to randomisation
  • Must be on airway clearance therapy, physiotherapy, or mucus clearance therapy.The dose and regimen of these therapies and any drugs used to aid expectoration should be stable for at least 3 months prior to the screening visit and remain stable throughout the DB period of the study.
  • If receiving inhaled or bronchodilator therapy, the dose and regimen should be stable with no alteration to dose or formulation for at least 3 months prior to the screening visit and this should remain stable throughout the DB period of the study.
  • Women of (WOCBP) must have a negative serum and urine pregnancy test prior to randomization and agree to use a highly effective method of from enrollment, throughout the study duration, and for 12 weeks after the last dose of IP.

Exclusion criteria

Exclusion Criteria:

  • Pulmonary disease other than bronchiectasis. Patients with a history of NTM disease may be enrolled if they have completed treatment prior to the Screening visit, if at least 3 months have elapsed since the last day of antibiotic treatment for NTM at the Screening visit, and if they have had a negative sputum culture prior to the screening visit.
  • Another diagnosed or suspected pulmonary or systemic disease associated with elevated peripheral eosinophil counts
  • Respiratory infection or bronchiectasis exacerbation during the screening period.
  • Any other clinical condition that is not stable in the opinion of the Investigator and could:

    1. Affect the safety of the patient during the study.
    2. Influence the findings of the study or their interpretation.
    3. Impede the patient's ability to complete the entire duration of the study.
  • Radiological findings suggestive of a respiratory disease other than bronchiectasis, suggestive of acute infection, or of solitary pulmonary nodules without appropriate follow up and demonstration of stability as per standard of care. Pulmonary nodules > 6 mm in size should have at least 2 years of follow up with no change on CT imaging.
  • Current active liver disease
  • Current , or history of malignancy, except for:

    1. Patients who have had basal cell carcinoma, localised squamous cell carcinoma of the skin, or in situ carcinoma of the cervix are eligible provided the patient is in remission and curative therapy was completed at least 12 months prior to Visit 1
    2. Patients who have had other malignancies are eligible provided that the participant is in remission and curative therapy was completed at least 5 years prior to Visit 1.
  • History of known immunodeficiency disorder including a positive test for , HIV-1 or HIV-2.
  • History of alcohol or drug abuse within the past year
  • Current smokers with a tobacco history of ≥ 10 pack-years or ex-smoker with a tobacco history of ≥ 10 pack-years.
  • Patients receiving long-term oxygen treatment
  • Patients participating in, or scheduled for, an intensive (active) pulmonary rehabilitation programme. Patients who are in the maintenance phase of a rehabilitation programme are eligible.
  • Use of non-invasive positive-pressure ventilation for conditions other than obstructive sleep apnoea
  • Use of medication within 3 months of the screening visit or expected need for chronic use (≥ 4 weeks) during study
  • Receipt of any marketed or biologic products (monoclonal or polyclonal antibody) within one year of the screening visit
  • Receipt of any investigational non-biologic product within 30 days or 5 half-lives prior to randomisation
  • Receipt of immunoglobulin and blood products within 30 days of the date of the screening visit
  • Receipt of within 30 days of the date of randomisation
  • Concurrent enrolment in another clinical drug interventional trial
  • History of anaphylaxis to any biologic therapy or vaccine
  • Known history of allergy or reaction to any component of the IP formulation.
  • Involvement in the planning and/or conduct of the study (applies to both AstraZeneca staff and/or staff at the study site)
  • Judgement by the Investigator that the patient should not participate in the study if the patient is unlikely to comply with study procedures, restrictions, and requirements
  • Previous randomisation in the present study
  • Currently pregnant (confirmed with positive pregnancy test) or breast-feeding.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
100 participants (actual)

Study arms

  • Experimental
    Benralizumab

    Benralizumab will be administered subcutaneously (SC) using an accessorized prefilled syringe (APFS)

    Biological: Benralizumab

  • Placebo comparator
    Placebo

    Matching placebo solution will be administered subcutaneously (SC) using an accessorized prefilled syringe (APFS)

    Biological: Placebo to Benralizumab

Interventions

  • BiologicalBenralizumab

    Benralizumab active solution in a single accessorized prefilled syringe (APFS) will be administered subcutaneously (SC), 1 mL fill volume

  • BiologicalPlacebo to Benralizumab

    Matching placebo solution in a single accessorized prefilled syringe (APFS) will be administered subcutaneously (SC), 1 mL fill volume

06

What researchers measure

Primary outcomes

  1. Annualized Bronchiectasis Exacerbations Rate in the Double-blind Period

    Annualized Non-Cystic Fibrosis Bronchiectasis (NCFB) exacerbations rate through end of double-blind treatment period.

    Time frame: through Double-blind period, at least 28 weeks and up to 52 weeks

Secondary outcomes

  1. Time to First Exacerbation in the Double-blind Treatment Period

    Time to first NCFB exacerbation in the double-blind treatment period

    Time frame: through Double-blind period, at least 28 weeks and up to 52 weeks

  2. Change From Baseline in QoL-B-RSS Over the Double-blind Period

    Change from baseline in Quality of Life-Bronchiectasis-Respiratory Symptoms Scale over the double-blind treatment period. QoL-B-RSS scores range from 0 to 100, with higher scores indicative of better health-related quality of life.

    Time frame: through Double-blind period, at least 28 weeks and up to 52 weeks

  3. Change From Baseline in Pre-dose Pre-BD FEV1 Over the Double-blind Treatment Period

    Change from baseline in pre-dose pre-bronchodilator (BD) forced expiratory volume in one second (FEV1) over the double-blind treatment period

    Time frame: through Double-blind period, at least 28 weeks and up to 52 weeks

  4. Change From Baseline in LCQ Total Score Over the Double-blind Period

    Change from baseline in Leicester Cough Questionnaire (LCQ) total score over the double-blind treatment period. LCQ total scores range from 3 to 21. Higher scores indicate better quality of life.

    Time frame: through Double-blind period, at least 28 weeks and up to 52 weeks

  5. Change From Baseline in QoL-B Scales (Excluding QoL-B-RSS) Over the Double-blind Period: Physical Functioning Scale

    change from baseline in Quality of Life-Bronchiectasis (QoL-B) scales (excluding QoL-B-RSS) over the double-blind treatment period: Physical Functioning Scale. QoL-B Physical Functioning Scale scores range from 0 to 100, with higher scores indicative of better health-related quality of life.

    Time frame: through Double-blind period, at least 28 weeks and up to 52 weeks

  6. Change From Baseline in QoL-B Scales (Excluding QoL-B-RSS) Over the Double-blind Period: Role Functioning Scale

    Change from baseline in Quality of Life-Bronchiectasis (QoL-B) scales (excluding QoL-B-RSS) over the double-blind treatment period: Role Functioning Scale. QoL-B Role Functioning Scale scores range from 0 to 100, with higher scores indicative of better health-related quality of life.

    Time frame: through Double-blind period, at least 28 weeks and up to 52 weeks

  7. Change From Baseline in QoL-B Scales (Excluding QoL-B-RSS) Over the Double-blind Period: Emotional Functioning Scale

    Change from baseline in Quality of Life-Bronchiectasis (QoL-B) scales (excluding QoL-B-RSS) over the double-blind treatment period: Emotional Functioning Scale. QoL-B Emotional Functioning Scale scores range from 0 to 100, with higher scores indicative of better health-related quality of life.

    Time frame: through Double-blind period, at least 28 weeks and up to 52 weeks

  8. Change From Baseline in QoL-B Scales (Excluding QoL-B-RSS) Over the Double-blind Period: Social Functioning Scale

    Change from baseline in Quality of Life-Bronchiectasis (QoL-B) scales (excluding QoL-B-RSS) over the double-blind treatment period: Social Functioning Scale. QoL-B Social Functioning Scale scores range from 0 to 100, with higher scores indicative of better health-related quality of life.

    Time frame: through Double-blind period, at least 28 weeks and up to 52 weeks

  9. Change From Baseline in QoL-B Scales (Excluding QoL-B-RSS) Over the Double-blind Period: Vitality Scale

    Change from baseline in Quality of Life-Bronchiectasis (QoL-B) scales (excluding QoL-B-RSS) over the double-blind treatment period: Vitality Scale. QoL-B Vitality Scale scores range from 0 to 100, with higher scores indicative of better health-related quality of life.

    Time frame: through Double-blind period, at least 28 weeks and up to 52 weeks

  10. Change From Baseline in QoL-B Scales (Excluding QoL-B-RSS) Over the Double-blind Period: Health Perceptions Scale

    Change from baseline in Quality of Life-Bronchiectasis (QoL-B) scales (excluding QoL-B-RSS) over the double-blind treatment period: Health Perceptions Scale. QoL-B Health Perceptions Scale scores range from 0 to 100, with higher scores indicative of better health-related quality of life.

    Time frame: through Double-blind period, at least 28 weeks and up to 52 weeks

  11. Change From Baseline in QoL-B Scales (Excluding QoL-B-RSS) Over the Double-blind Period: Treatment Burden Scale

    Change from baseline in Quality of Life-Bronchiectasis (QoL-B) scales (excluding QoL-B-RSS) over the double-blind treatment period: Treatment Burden Scale. QoL-B Treatment Burden Scale scores range from 0 to 100, with higher scores indicative of better health-related quality of life.

    Time frame: through Double-blind period, at least 28 weeks and up to 52 weeks

  12. Change From Baseline in SGRQ Total Score Over the Double-blind Treatment Period

    Change from baseline in St. George's Respiratory Questionnaire (SGRQ) total score over the double-blind treatment period. SGRQ total scores range from 0 to 100. 100 represents the worst possible health status and 0 indicates the best possible health status.

    Time frame: through Double-blind period, at least 28 weeks and up to 52 weeks

07

Results

Posted Jul 20, 2025

Participant flow

The plan was to randomize 420 eligible patients in a 1:1 ratio to receive either benralizumab or a matching placebo after screening. Patients were stratified at randomization by screening blood eosinophil category, country, and current chronic macrolide use. Due to the decision to stop recruitment early, 100 patients were randomized to receive benralizumab or placebo (20:80 in the low \& high blood eosinophil strata). The revised DB treatment period was at least 28 weeks and up to 52 weeks.

Double-blind Treatment Period
Participant flow — Double-blind Treatment Period
MilestoneBenralizumab 30 mgPlacebo
Started5445
Treated5445
Completed4242
Not completed123
Withdrew: Physician decision20
Withdrew: Study terminated by sponsor10
Withdrew: Withdrawal by subject72
Withdrew: Protocol violation20
Withdrew: Subject decision without consent withdrawn01
Open-label Extension Period
Participant flow — Open-label Extension Period
MilestoneBenralizumab 30 mgPlacebo
Started3840
Completed3839
Not completed01
Withdrew: Subject decision without consent withdrawn01

Outcome measures

PrimaryAnnualized Bronchiectasis Exacerbations Rate in the Double-blind Period

Annualized Non-Cystic Fibrosis Bronchiectasis (NCFB) exacerbations rate through end of double-blind treatment period.

Time frame:
through Double-blind period, at least 28 weeks and up to 52 weeks
Reported as:
Least squares mean · exacerbations per year
Annualized Bronchiectasis Exacerbations Rate in the Double-blind Period
exacerbations per yearBenralizumab 30 mgPlacebo
Annualized Bronchiectasis Exacerbations Rate in the Double-blind Period1.44 (1.05 to 1.97)1.27 (0.89 to 1.80)
Statistical analysis
  • Benralizumab 30 mg vs Placebo · negative binomial model · p = 0.5911 · Risk ratio (rr): 1.14 · 95% CI 0.71 to 1.82The rate ratio (Benralizumab/Placebo) and its 95% CI are estimated using a negative binomial model. The covariates include treatment arm, baseline blood eosinophil category, and number of exacerbations from previous year.
SecondaryTime to First Exacerbation in the Double-blind Treatment Period

Time to first NCFB exacerbation in the double-blind treatment period

Time frame:
through Double-blind period, at least 28 weeks and up to 52 weeks
Reported as:
Median · days
Time to First Exacerbation in the Double-blind Treatment Period
daysBenralizumab 30 mgPlacebo
Time to First Exacerbation in the Double-blind Treatment Period233 (118 to NA)316 (141 to NA)
Statistical analysis
  • Benralizumab 30 mg vs Placebo · Regression, Cox · p = 0.6677 · Hazard ratio (hr): 1.12 · 95% CI 0.67 to 1.91The analysis is performed using cox proportional hazards model with covariates of treatment group, number of exacerbations in previous year and baseline eosinophil category.
SecondaryChange From Baseline in QoL-B-RSS Over the Double-blind Period

Change from baseline in Quality of Life-Bronchiectasis-Respiratory Symptoms Scale over the double-blind treatment period. QoL-B-RSS scores range from 0 to 100, with higher scores indicative of better health-related quality of life.

Time frame:
through Double-blind period, at least 28 weeks and up to 52 weeks
Reported as:
Mean · score on a scale
Change From Baseline in QoL-B-RSS Over the Double-blind Period
score on a scaleBenralizumab 30 mgPlacebo
Week 26.6 ± 12.573.1 ± 11.65
Week 45.8 ± 12.53-1.5 ± 12.49
Week 66.8 ± 14.390.7 ± 10.94
Week 86.6 ± 14.172.1 ± 16.29
Week 105.3 ± 13.02-1.0 ± 14.46
Week 127.2 ± 11.470.9 ± 15.44
Week 148.0 ± 12.283.7 ± 14.63
Week 166.2 ± 14.511.3 ± 15.79
Week 188.6 ± 14.412.6 ± 18.60
Week 208.6 ± 15.411.4 ± 18.58
Week 228.4 ± 13.303.9 ± 20.33
Week 249.3 ± 17.314.4 ± 17.70
Week 267.4 ± 15.073.8 ± 18.40
Week 286.5 ± 15.922.7 ± 21.33
Week 307.5 ± 14.261.2 ± 17.32
Week 3212.1 ± 14.372.4 ± 19.09
Week 347.6 ± 12.582.8 ± 18.90
Week 369.6 ± 17.443.6 ± 19.31
Week 388.1 ± 14.961.3 ± 17.68
Week 409.6 ± 17.32-1.1 ± 18.50
Week 427.1 ± 14.933.3 ± 16.25
Week 447.5 ± 15.000.8 ± 20.76
Week 468.6 ± 17.763.4 ± 18.89
Week 488.1 ± 16.753.2 ± 20.52
Week 509.8 ± 14.630.1 ± 15.42
Week 527.3 ± 17.910.2 ± 18.12
SecondaryChange From Baseline in Pre-dose Pre-BD FEV1 Over the Double-blind Treatment Period

Change from baseline in pre-dose pre-bronchodilator (BD) forced expiratory volume in one second (FEV1) over the double-blind treatment period

Time frame:
through Double-blind period, at least 28 weeks and up to 52 weeks
Reported as:
Mean · L
Change From Baseline in Pre-dose Pre-BD FEV1 Over the Double-blind Treatment Period
LBenralizumab 30 mgPlacebo
Week 40.0139 ± 0.14327-0.0477 ± 0.10758
Week 80.0048 ± 0.15392-0.0465 ± 0.15263
Week 16-0.0191 ± 0.15964-0.0282 ± 0.11452
Week 24-0.0378 ± 0.17290-0.0595 ± 0.16409
Week 32-0.0248 ± 0.16782-0.0921 ± 0.17543
Week 40-0.0597 ± 0.18924-0.1037 ± 0.16808
Week 48-0.1236 ± 0.16353-0.0849 ± 0.13783
Week 52-0.1093 ± 0.13130-0.1186 ± 0.14969
SecondaryChange From Baseline in LCQ Total Score Over the Double-blind Period

Change from baseline in Leicester Cough Questionnaire (LCQ) total score over the double-blind treatment period. LCQ total scores range from 3 to 21. Higher scores indicate better quality of life.

Time frame:
through Double-blind period, at least 28 weeks and up to 52 weeks
Reported as:
Mean · score on a scale
Change From Baseline in LCQ Total Score Over the Double-blind Period
score on a scaleBenralizumab 30 mgPlacebo
Week 20.5 ± 2.220.5 ± 2.13
Week 40.7 ± 2.350.0 ± 2.15
Week 60.8 ± 2.760.6 ± 2.56
Week 80.8 ± 3.370.3 ± 2.85
Week 101.0 ± 2.770.1 ± 2.76
Week 121.0 ± 2.510.4 ± 3.03
Week 141.4 ± 2.780.8 ± 3.16
Week 160.9 ± 2.610.5 ± 3.10
Week 181.0 ± 3.421.1 ± 3.55
Week 201.4 ± 3.280.8 ± 3.39
Week 220.9 ± 3.320.8 ± 4.03
Week 241.0 ± 3.431.2 ± 3.48
Week 260.9 ± 3.581.0 ± 3.54
Week 280.5 ± 4.310.9 ± 4.08
Week 300.7 ± 3.330.8 ± 4.06
Week 321.8 ± 3.450.7 ± 4.14
Week 340.8 ± 2.430.8 ± 3.92
Week 361.2 ± 3.480.8 ± 3.95
Week 381.0 ± 3.610.6 ± 4.24
Week 401.2 ± 3.930.2 ± 3.86
Week 420.6 ± 3.420.3 ± 4.19
Week 440.5 ± 3.230.3 ± 4.02
Week 460.7 ± 3.680.6 ± 4.22
Week 480.3 ± 3.780.5 ± 4.20
Week 500.7 ± 3.29-0.2 ± 3.41
Week 520.2 ± 3.94-0.1 ± 2.86
SecondaryChange From Baseline in QoL-B Scales (Excluding QoL-B-RSS) Over the Double-blind Period: Physical Functioning Scale

change from baseline in Quality of Life-Bronchiectasis (QoL-B) scales (excluding QoL-B-RSS) over the double-blind treatment period: Physical Functioning Scale. QoL-B Physical Functioning Scale scores range from 0 to 100, with higher scores indicative of better health-related quality of life.

Time frame:
through Double-blind period, at least 28 weeks and up to 52 weeks
Reported as:
Mean · score on a scale
Change From Baseline in QoL-B Scales (Excluding QoL-B-RSS) Over the Double-blind Period: Physical Functioning Scale
score on a scaleBenralizumab 30 mgPlacebo
Week 20.5 ± 12.23-0.0 ± 16.50
Week 41.5 ± 17.680.8 ± 19.39
Week 64.1 ± 20.810.2 ± 17.97
Week 83.3 ± 15.070.3 ± 20.81
Week 101.5 ± 19.221.0 ± 22.06
Week 123.1 ± 19.540.5 ± 21.89
Week 144.4 ± 15.484.2 ± 22.15
Week 163.5 ± 18.063.3 ± 25.17
Week 184.8 ± 19.152.2 ± 23.01
Week 204.5 ± 18.454.7 ± 25.18
Week 223.1 ± 19.622.2 ± 22.96
Week 245.2 ± 18.214.7 ± 23.03
Week 263.6 ± 20.683.6 ± 24.40
Week 283.8 ± 24.774.8 ± 24.39
Week 302.5 ± 21.334.8 ± 25.50
Week 326.7 ± 18.805.9 ± 24.73
Week 342.7 ± 19.143.5 ± 24.90
Week 360.6 ± 22.764.7 ± 24.78
Week 381.9 ± 16.403.5 ± 23.5
Week 402.1 ± 23.554.1 ± 25.01
Week 421.3 ± 21.135.5 ± 28.92
Week 440.6 ± 23.624.2 ± 24.03
Week 462.0 ± 22.897.9 ± 23.42
Week 480.0 ± 27.897.6 ± 22.98
Week 505.3 ± 23.461.3 ± 21.08
Week 525.1 ± 23.902.1 ± 19.25
SecondaryChange From Baseline in QoL-B Scales (Excluding QoL-B-RSS) Over the Double-blind Period: Role Functioning Scale

Change from baseline in Quality of Life-Bronchiectasis (QoL-B) scales (excluding QoL-B-RSS) over the double-blind treatment period: Role Functioning Scale. QoL-B Role Functioning Scale scores range from 0 to 100, with higher scores indicative of better health-related quality of life.

Time frame:
through Double-blind period, at least 28 weeks and up to 52 weeks
Reported as:
Mean · score on a scale
Change From Baseline in QoL-B Scales (Excluding QoL-B-RSS) Over the Double-blind Period: Role Functioning Scale
score on a scaleBenralizumab 30 mgPlacebo
Week 21.1 ± 13.64-1.2 ± 11.11
Week 42.8 ± 13.00-0.3 ± 14.53
Week 62.7 ± 14.802.5 ± 12.05
Week 80.5 ± 16.270.2 ± 15.02
Week 101.2 ± 14.092.7 ± 16.32
Week 121.7 ± 16.362.3 ± 16.96
Week 143.0 ± 16.102.1 ± 16.70
Week 160.1 ± 17.77-0.3 ± 16.60
Week 182.4 ± 16.93-0.0 ± 17.67
Week 200.9 ± 16.010.5 ± 18.25
Week 222.8 ± 21.114.0 ± 20.47
Week 241.9 ± 22.600.6 ± 19.67
Week 26-0.1 ± 21.441.2 ± 18.36
Week 28-1.9 ± 21.022.7 ± 17.79
Week 301.1 ± 20.83-0.3 ± 19.04
Week 324.4 ± 15.080.2 ± 18.17
Week 341.4 ± 18.011.7 ± 17.97
Week 36-0.6 ± 19.180.5 ± 16.69
Week 381.4 ± 18.15-2.2 ± 19.65
Week 401.7 ± 22.200.2 ± 21.80
Week 42-1.3 ± 21.481.8 ± 20.19
Week 440.6 ± 25.33-1.4 ± 17.46
Week 460.4 ± 23.894.0 ± 19.00
Week 48-1.2 ± 25.030.2 ± 18.16
Week 500.7 ± 21.26-1.9 ± 12.55
Week 52-0.8 ± 23.281.1 ± 17.81
SecondaryChange From Baseline in QoL-B Scales (Excluding QoL-B-RSS) Over the Double-blind Period: Emotional Functioning Scale

Change from baseline in Quality of Life-Bronchiectasis (QoL-B) scales (excluding QoL-B-RSS) over the double-blind treatment period: Emotional Functioning Scale. QoL-B Emotional Functioning Scale scores range from 0 to 100, with higher scores indicative of better health-related quality of life.

Time frame:
through Double-blind period, at least 28 weeks and up to 52 weeks
Reported as:
Mean · score on a scale
Change From Baseline in QoL-B Scales (Excluding QoL-B-RSS) Over the Double-blind Period: Emotional Functioning Scale
score on a scaleBenralizumab 30 mgPlacebo
Week 20.2 ± 13.632.0 ± 17.43
Week 4-0.7 ± 14.071.4 ± 14.42
Week 63.5 ± 17.994.2 ± 14.98
Week 8-1.2 ± 16.841.4 ± 17.77
Week 100.2 ± 16.43-1.0 ± 16.58
Week 122.8 ± 17.301.6 ± 21.38
Week 144.7 ± 14.311.8 ± 20.79
Week 162.2 ± 16.561.2 ± 22.48
Week 183.2 ± 15.573.8 ± 21.68
Week 203.9 ± 15.821.4 ± 22.27
Week 222.8 ± 18.462.1 ± 23.09
Week 242.4 ± 17.802.9 ± 19.32
Week 263.0 ± 17.154.3 ± 22.00
Week 280.4 ± 25.821.6 ± 24.43
Week 302.7 ± 22.551.5 ± 23.79
Week 324.0 ± 15.823.0 ± 22.42
Week 341.4 ± 19.641.9 ± 23.23
Week 361.9 ± 17.894.5 ± 22.75
Week 382.6 ± 20.791.9 ± 22.64
Week 401.7 ± 23.352.3 ± 22.28
Week 421.1 ± 21.973.4 ± 22.67
Week 441.9 ± 25.891.8 ± 18.95
Week 463.9 ± 22.026.8 ± 22.77
Week 485.8 ± 22.105.4 ± 22.83
Week 505.5 ± 20.693.0 ± 18.14
Week 526.0 ± 26.300.9 ± 24.98
SecondaryChange From Baseline in QoL-B Scales (Excluding QoL-B-RSS) Over the Double-blind Period: Social Functioning Scale

Change from baseline in Quality of Life-Bronchiectasis (QoL-B) scales (excluding QoL-B-RSS) over the double-blind treatment period: Social Functioning Scale. QoL-B Social Functioning Scale scores range from 0 to 100, with higher scores indicative of better health-related quality of life.

Time frame:
through Double-blind period, at least 28 weeks and up to 52 weeks
Reported as:
Mean · score on a scale
Change From Baseline in QoL-B Scales (Excluding QoL-B-RSS) Over the Double-blind Period: Social Functioning Scale
score on a scaleBenralizumab 30 mgPlacebo
Week 26.4 ± 17.604.5 ± 17.35
Week 44.4 ± 18.626.3 ± 22.69
Week 68.4 ± 21.605.8 ± 20.05
Week 89.7 ± 23.109.2 ± 20.53
Week 109.4 ± 19.646.0 ± 20.31
Week 1210.6 ± 23.325.8 ± 21.42
Week 1410.9 ± 23.037.7 ± 20.52
Week 169.1 ± 20.736.0 ± 23.53
Week 1811.6 ± 21.6110.3 ± 22.43
Week 2011.8 ± 22.598.9 ± 21.43
Week 227.2 ± 20.429.5 ± 24.09
Week 2410.1 ± 24.9010.7 ± 24.14
Week 2610.1 ± 22.869.9 ± 22.46
Week 288.8 ± 24.678.7 ± 24.83
Week 3010.2 ± 26.577.7 ± 24.82
Week 3212.8 ± 23.848.6 ± 24.48
Week 349.6 ± 27.939.3 ± 24.95
Week 3612.0 ± 27.068.1 ± 25.53
Week 3810.2 ± 27.836.5 ± 25.41
Week 4013.9 ± 32.358.3 ± 27.77
Week 4210.2 ± 29.408.6 ± 28.16
Week 449.9 ± 28.681.8 ± 24.50
Week 469.1 ± 27.406.6 ± 29.11
Week 4812.1 ± 27.113.9 ± 30.74
Week 5010.2 ± 23.60-1.7 ± 26.85
Week 5211.6 ± 27.912.3 ± 25.29
SecondaryChange From Baseline in QoL-B Scales (Excluding QoL-B-RSS) Over the Double-blind Period: Vitality Scale

Change from baseline in Quality of Life-Bronchiectasis (QoL-B) scales (excluding QoL-B-RSS) over the double-blind treatment period: Vitality Scale. QoL-B Vitality Scale scores range from 0 to 100, with higher scores indicative of better health-related quality of life.

Time frame:
through Double-blind period, at least 28 weeks and up to 52 weeks
Reported as:
Mean · score on a scale
Change From Baseline in QoL-B Scales (Excluding QoL-B-RSS) Over the Double-blind Period: Vitality Scale
score on a scaleBenralizumab 30 mgPlacebo
Week 23.0 ± 18.77-2.4 ± 13.54
Week 43.1 ± 17.820.3 ± 15.21
Week 64.0 ± 18.83-2.0 ± 13.88
Week 84.9 ± 17.84-1.1 ± 16.26
Week 106.4 ± 16.32-3.1 ± 18.83
Week 125.8 ± 18.48-3.9 ± 16.24
Week 148.8 ± 20.69-2.7 ± 18.22
Week 165.2 ± 19.66-0.5 ± 19.71
Week 185.0 ± 19.78-1.4 ± 18.69
Week 207.1 ± 19.99-1.3 ± 19.28
Week 225.7 ± 21.66-0.6 ± 21.04
Week 244.1 ± 20.871.0 ± 19.67
Week 266.2 ± 20.18-1.6 ± 20.66
Week 283.9 ± 21.75-2.1 ± 21.57
Week 304.4 ± 21.84-4.3 ± 22.74
Week 326.1 ± 19.970.0 ± 20.49
Week 341.1 ± 18.98-0.8 ± 20.96
Week 361.0 ± 18.59-2.7 ± 18.72
Week 384.1 ± 18.88-0.0 ± 19.52
Week 402.6 ± 23.01-2.7 ± 21.97
Week 423.0 ± 21.54-1.0 ± 24.37
Week 442.9 ± 21.11-3.4 ± 21.24
Week 465.2 ± 24.651.0 ± 20.10
Week 482.0 ± 23.48-1.3 ± 20.97
Week 507.7 ± 20.810.0 ± 18.14
Week 525.3 ± 18.74-5.3 ± 23.53
SecondaryChange From Baseline in QoL-B Scales (Excluding QoL-B-RSS) Over the Double-blind Period: Health Perceptions Scale

Change from baseline in Quality of Life-Bronchiectasis (QoL-B) scales (excluding QoL-B-RSS) over the double-blind treatment period: Health Perceptions Scale. QoL-B Health Perceptions Scale scores range from 0 to 100, with higher scores indicative of better health-related quality of life.

Time frame:
through Double-blind period, at least 28 weeks and up to 52 weeks
Reported as:
Mean · score on a scale
Change From Baseline in QoL-B Scales (Excluding QoL-B-RSS) Over the Double-blind Period: Health Perceptions Scale
score on a scaleBenralizumab 30 mgPlacebo
Week 21.3 ± 12.953.3 ± 14.12
Week 41.2 ± 14.87-0.2 ± 16.72
Week 63.5 ± 16.903.7 ± 16.06
Week 85.3 ± 17.234.3 ± 18.46
Week 105.6 ± 16.572.1 ± 18.47
Week 127.5 ± 16.693.3 ± 17.74
Week 147.4 ± 16.781.4 ± 18.99
Week 161.9 ± 16.252.4 ± 20.35
Week 185.8 ± 16.681.7 ± 20.69
Week 204.6 ± 18.213.9 ± 21.70
Week 225.0 ± 16.706.3 ± 21.99
Week 247.2 ± 17.185.0 ± 19.85
Week 262.8 ± 16.765.0 ± 20.26
Week 283.4 ± 18.812.4 ± 20.68
Week 304.5 ± 18.034.3 ± 21.87
Week 327.0 ± 16.372.4 ± 20.09
Week 344.2 ± 17.682.9 ± 22.29
Week 363.5 ± 17.842.0 ± 20.56
Week 384.2 ± 16.303.0 ± 22.90
Week 405.1 ± 16.951.4 ± 22.35
Week 424.7 ± 18.384.4 ± 23.77
Week 444.8 ± 21.031.5 ± 20.78
Week 466.6 ± 22.451.8 ± 19.07
Week 487.3 ± 21.323.9 ± 23.68
Week 506.9 ± 20.424.7 ± 18.65
Week 524.0 ± 21.530.4 ± 24.13
SecondaryChange From Baseline in QoL-B Scales (Excluding QoL-B-RSS) Over the Double-blind Period: Treatment Burden Scale

Change from baseline in Quality of Life-Bronchiectasis (QoL-B) scales (excluding QoL-B-RSS) over the double-blind treatment period: Treatment Burden Scale. QoL-B Treatment Burden Scale scores range from 0 to 100, with higher scores indicative of better health-related quality of life.

Time frame:
through Double-blind period, at least 28 weeks and up to 52 weeks
Reported as:
Mean · score on a scale
Change From Baseline in QoL-B Scales (Excluding QoL-B-RSS) Over the Double-blind Period: Treatment Burden Scale
score on a scaleBenralizumab 30 mgPlacebo
Week 23.6 ± 22.56-2.2 ± 16.75
Week 43.7 ± 18.62-2.1 ± 13.34
Week 66.0 ± 23.20-2.1 ± 15.72
Week 84.8 ± 18.35-1.9 ± 14.87
Week 104.0 ± 17.311.1 ± 17.83
Week 120.3 ± 17.27-0.4 ± 12.54
Week 140.6 ± 20.74-4.1 ± 14.73
Week 164.4 ± 20.10-1.1 ± 16.34
Week 18-1.9 ± 16.28-1.2 ± 14.92
Week 204.1 ± 16.010.3 ± 15.84
Week 22-1.3 ± 14.37-0.8 ± 16.82
Week 24-1.0 ± 18.58-1.1 ± 14.45
Week 261.9 ± 17.322.5 ± 15.37
Week 28-5.1 ± 24.001.4 ± 15.11
Week 30-2.0 ± 19.14-1.1 ± 18.39
Week 32-2.1 ± 16.32-0.8 ± 15.12
Week 34-0.4 ± 16.70-4.0 ± 17.95
Week 36-0.7 ± 16.68-1.5 ± 16.69
Week 38-4.2 ± 25.27-2.9 ± 21.04
Week 40-2.0 ± 24.76-0.4 ± 16.15
Week 42-1.5 ± 23.521.7 ± 18.78
Week 442.1 ± 17.221.4 ± 21.00
Week 46-0.0 ± 18.594.6 ± 14.62
Week 48-0.9 ± 17.253.6 ± 19.96
Week 50-2.0 ± 22.13-1.9 ± 18.77
Week 52-1.9 ± 25.641.7 ± 14.94
SecondaryChange From Baseline in SGRQ Total Score Over the Double-blind Treatment Period

Change from baseline in St. George's Respiratory Questionnaire (SGRQ) total score over the double-blind treatment period. SGRQ total scores range from 0 to 100. 100 represents the worst possible health status and 0 indicates the best possible health status.

Time frame:
through Double-blind period, at least 28 weeks and up to 52 weeks
Reported as:
Mean · score on a scale
Change From Baseline in SGRQ Total Score Over the Double-blind Treatment Period
score on a scaleBenralizumab 30 mgPlacebo
Week 4-4.7 ± 14.920.6 ± 14.89
Week 8-4.3 ± 15.99-2.4 ± 15.33
Week 16-4.4 ± 15.03-0.1 ± 16.06
Week 24-6.3 ± 16.21-3.9 ± 21.08
Week 32-5.8 ± 15.73-1.6 ± 21.46
Week 40-5.8 ± 17.63-1.6 ± 24.51
Week 48-4.9 ± 18.58-0.0 ± 22.45
Week 52-4.4 ± 20.374.8 ± 23.33

Adverse events

Collected over Double-Blind Treatment Period: From first dose of study drug until end of double-blind period, up to 52 weeks. Open-label Extension Period: From the end of the double-blind period (week 25 to 53) to the end of open-label extension period, up to 40 weeks.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Benra 30 mg - DB0/54 (0%)10/54 (18.5%)33/54 (61.1%)
Placebo - DB0/45 (0%)3/45 (6.7%)18/45 (40%)
Benra 30 mg - OLE0/38 (0%)5/38 (13.2%)9/38 (23.7%)
Placebo Swithed to Benra 30 mg - OLE0/40 (0%)4/40 (10%)9/40 (22.5%)
Most frequent serious events
Showing 10 of 11
Most frequent serious events
EventBenra 30 mg - DBPlacebo - DBBenra 30 mg - OLEPlacebo Swithed to Benra 30 mg - OLE
BronchiectasisRespiratory, thoracic and mediastinal disorders8/543/452/383/40
Incarcerated inguinal herniaGastrointestinal disorders0/540/451/380/40
Intestinal obstructionGastrointestinal disorders0/540/451/380/40
COVID-19Infections and infestations0/540/451/380/40
Pneumonia pseudomonalInfections and infestations0/540/451/380/40
HypertensionVascular disorders0/540/450/381/40
Acute respiratory failureRespiratory, thoracic and mediastinal disorders1/540/450/380/40
Pulmonary embolismRespiratory, thoracic and mediastinal disorders1/540/450/380/40
EnteritisGastrointestinal disorders1/540/450/380/40
Haemophilus infectionInfections and infestations1/540/450/380/40
Most frequent other events
Showing 10 of 12
Most frequent other events
EventBenra 30 mg - DBPlacebo - DBBenra 30 mg - OLEPlacebo Swithed to Benra 30 mg - OLE
COVID-19Infections and infestations18/5410/453/381/40
HeadacheNervous system disorders5/545/450/382/40
NasopharyngitisInfections and infestations5/545/452/381/40
Back painMusculoskeletal and connective tissue disorders4/542/450/381/40
Gastrooesophageal reflux diseaseGastrointestinal disorders4/540/450/380/40
PyrexiaGeneral disorders1/543/450/380/40
Abdominal pain upperGastrointestinal disorders3/540/450/380/40
FatigueGeneral disorders3/540/450/381/40
SinusitisInfections and infestations3/541/451/382/40
Upper respiratory tract infectionInfections and infestations3/541/451/381/40

Baseline characteristics

All participants who were randomized and received any Investigational Product were included in the full analysis set.

Age, Continuous
Age, Continuous(years)Benralizumab 30 mgPlaceboTotal
Mean59.2 ± 13.1459.2 ± 15.4959.2 ± 14.18
Age, Customized
Age, Customized(participants)Benralizumab 30 mgPlaceboTotal
>= 18 to <= 65 years342155
> 65 years202444
Sex: Female, Male
Sex: Female, Male(Participants)Benralizumab 30 mgPlaceboTotal
Female373572
Male171027
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Benralizumab 30 mgPlaceboTotal
Hispanic or Latino4711
Not Hispanic or Latino503888
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Benralizumab 30 mgPlaceboTotal
American Indian or Alaska Native000
Asian171431
Native Hawaiian or Other Pacific Islander000
Black or African American000
White363167
More than one race101
Unknown or Not Reported000
08

Study locations

48 sites
  • Research Site
    Birmingham, Alabama 35233, United States
  • Research Site
    Newport Beach, California 92663, United States
  • Research Site
    Northridge, California 91324, United States
  • Research Site
    El Paso, Texas 79902, United States
  • Research Site
    Florida, B1602DQD, Argentina
  • Research Site
    San Fernando, B1646EBJ, Argentina
  • Research Site
    San Miguel de Tucumán, 4000, Argentina
  • Research Site
    Melbourne, 3004, Australia
  • Research Site
    South Brisbane, 4101, Australia
  • Research Site
    Ajax, Ontario L1S 2J5, Canada
  • Research Site
    Burlington, Ontario L7N 3V2, Canada
  • Research Site
    Windsor, Ontario N8X-5A6, Canada
  • Research Site
    Guangzhou, 510120, China
  • Research Site
    Guangzhou, China
  • Research Site
    Shanghai, 200032, China
  • Research Site
    Zhengzhou, 450000, China
  • Research Site
    Aalborg, 9000, Denmark
  • Research Site
    Hellerup, 2900, Denmark
  • Research Site
    Hvidovre, 2650, Denmark
  • Research Site
    Vejle, 7100, Denmark
  • Research Site
    Essen, 45239, Germany
  • Research Site
    Frankfurt, 60590, Germany
  • Research Site
    Gauting, 82131, Germany
  • Research Site
    München, D-80336, Germany
  • Research Site
    Coimbatore, 641028, India
  • Research Site
    Hyderabad, 500084, India
  • Research Site
    New Delhi, 100049, India
  • Research Site
    Milan, 20122, Italy
  • Research Site
    Pisa, 56100, Italy
  • Research Site
    Roma, 00168, Italy
  • Research Site
    Rozzano, 20089, Italy
  • Research Site
    Quezon City, 1100, Philippines
  • Research Site
    Bydgoszcz, 85-079, Poland
  • Research Site
    Ostrowiec Świętokrzyski, 27-400, Poland
  • Research Site
    Wroclaw, 54-239, Poland
  • Research Site
    Penza, 440067, Russia
  • Research Site
    Saratov, 410012, Russia
  • Research Site
    Ulyanovsk, 432009, Russia
  • Research Site
    Jeonju, 54907, South Korea
  • Research Site
    Seoul, 04763, South Korea
  • Research Site
    Seoul, 05030, South Korea
  • Research Site
    Seoul, 06591, South Korea
  • Research Site
    Barcelona, 08003, Spain
  • Research Site
    Madrid, 28040, Spain
  • Research Site
    Southampton, SO9 4XY, United Kingdom
  • Research Site
    Hanoi, 100000, Vietnam
  • Research Site
    Ho Chi Minh City, 700000, Vietnam
  • Research Site
    Hochiminh, 70000, Vietnam
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Supporting information: Study protocol, Statistical analysis plan

Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please refer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Access criteria: When a request has been approved AstraZeneca will provide access to the de-identified individual patient-level data in an approved sponsored tool. Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Data sharing details ↗ · astrazenecagroup-dt.pharmacm.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jul 2021 to primary completion in Apr 2024, 32 months.

Results were first posted in Jul 2025, 1 year 3 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 23, 2021
First posted
Aug 16, 2021
StartActual
Jul 21, 2021
Primary completionActual
Apr 16, 2024
CompletionActual
Apr 16, 2024
Results first posted
Jul 20, 2025
Last update
Jul 20, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 20, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05006573
Lead sponsor
AstraZeneca
Responsible party
Sponsor
First posted
Aug 16, 2021
Start date
Jul 21, 2021
Primary completion
Apr 16, 2024
Completion
Apr 16, 2024
Results posted
Jul 20, 2025
Last update
Jul 20, 2025

Study contacts

James D. Chalmers, MD
principal investigator · University of Dundee, Nethergate, Dundee DD1 4HN, Scotland, UK

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Jul 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Benralizumab

Start the discussion